Azitromicin
Izgled
(IUPAC) ime | |||
---|---|---|---|
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11[(2S,3R,4S,6R)-4-(dimetilamino)-3-hidroksi-6-metiloksan-2-il]oksi2-etil-3,4,10-trihidroksi-13[(2R,4R,5S,6S)-5-hidroksi-4-metoksi-4,6-dimetiloksan-2-il]oksi3,5,6,8,10,12,14-heptametil-1-oksa-6-azaciklopentadekan-15-on | |||
Klinički podaci | |||
Robne marke | Azenil, Azibiot, Azifine, Azitromax | ||
AHFS/Drugs.com | Monografija | ||
Identifikatori | |||
CAS broj | 83905-01-5 | ||
ATC kod | J01FA10 , S01AA26 | ||
DrugBank | DB00207 | ||
KEGG[1] | C06838 | ||
ChEMBL[2] | CHEMBL2955 | ||
Hemijski podaci | |||
Formula | C38H72N2O12 | ||
Mol. masa | 748.9845 | ||
SMILES | eMolekuli & PubHem | ||
| |||
Fizički podaci | |||
Tačka topljenja | 114 °C (237 °F) | ||
Farmakokinetički podaci | |||
Poluvreme eliminacije | 68 sati | ||
Izlučivanje | Bilijarno, uglavnom nepromenjen lek | ||
Farmakoinformacioni podaci | |||
Trudnoća | ? | ||
Pravni status | |||
Način primene | Intravenozno; Oralno |
Azitromicin je polusintetički makrolidni antibiotik azalidne klase. Poput drugih makrolidnih antibiotika, azitromicin inhibira bakterijsku proteinsku sintezu vezivanjem za 50S ribozomalnu podjedinicu bakterijskog 70S ribozoma.[3][4][5]
- ↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ Noedl H, Krudsood S, Chalermratana K, Silachamroon U, Leowattana W, Tangpukdee N, Looareesuwan S, Miller RS, Fukuda M, Jongsakul K, Sriwichai S, Rowan J, Bhattacharyya H, Ohrt C, Knirsch C: Azithromycin combination therapy with artesunate or quinine for the treatment of uncomplicated Plasmodium falciparum malaria in adults: a randomized, phase 2 clinical trial in Thailand. Clin Infect Dis. 2006 Nov 15;43(10):1264-71. Epub 2006 Oct 12. PMID 17051490
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. PMID 21059682.
- ↑ Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. PMID 18048412.